Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Histoplasmosis: later-stage trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Histoplasmosis: 3 US clinical trials tracked, none currently recruiting.
Histoplasmosis is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Scynexis, running 1 of these trials.
Enrollment posture brief
Registry condition histoplasmosis
OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Histoplasmosis has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Histoplasmosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Histoplasmosis is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Scynexis
NCT03059992
Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000627
A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients
Janssen
NCT00002438
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Named interventions
Most-linked intervention names on Histoplasmosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Histoplasmosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Histoplasmosis page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Histoplasmosis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Scynexis sponsors the most Histoplasmosis trials on record, review their full trial history before evaluating a specific study. See Scynexis's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Histoplasmosis condition card totals 3 registered trials; most-linked intervention Ibrexafungerp; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.